TAL
IOVA icon

TIG Advisors LLC’s Iovance Biotherapeutics IOVA Stock Holding History

TIG Advisors LLC’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-266,979
Closed -$7.99M – 48
2020
Q1 		$7.99M Buy
+266,979
New +$7.08M 0.32% 36

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

TIG Advisors LLC's IOVA Position: Q2 2020 in Review

TIG Advisors LLC sold out of Iovance Biotherapeutics (IOVA) in Q2 2020, closing a stake of 266,979 shares — an estimated $7.99M sold.

TIG Advisors LLC first reported a position in IOVA in Q1 2020 and held it in 1 quarter. The position peaked at $7.99M in Q1 2020. 257 funds tracked by Wall St. Rank hold IOVA as of Q2 2020.

  • TIG Advisors LLC reported no remaining Iovance Biotherapeutics position as of Q2 2020 after selling out during the quarter.
  • TIG Advisors LLC sold 266,979 Iovance Biotherapeutics shares in Q2 2020, an estimated $7.99M.
  • TIG Advisors LLC first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 1 quarter.
  • TIG Advisors LLC's Iovance Biotherapeutics position peaked at $7.99M in Q1 2020.
  • 257 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2020.

Based on TIG Advisors LLC's 13F filing for Q2 2020, filed 14 Aug 2020.